期刊文献+

检测重组人鼠嵌合抗VEGFR2单克隆抗体的ELISA方法的建立

Development of ELISA Method of Determining Recombinant Human Chimeric Mouse of Anti-VEGFR2 Monoclonal Antibody
下载PDF
导出
摘要 目的:建立一种新型、快速定量检测食蟹猴血清中抗血管内皮生长因子受体2(VEGFR2)单克隆抗体浓度的方法.方法:将特异性抗原VEGFR2-His包被在固相载体上,加稀释的受试药品血清,然后加入HRP标记的羊抗人IgG-(h+1),再加入TMB显色液,最后加入1 mol/L硫酸终止液,在酶标仪上用双波长读取D4s450/560nm值.结果:建立了定量检测食蟹猴血清中抗VEGFR2单克隆抗体浓度的ELISA法,方法的线性范围为400~6.25 ng/mL,定量下限为6.25ng/mL,板内精密度介于-13.6%~8.3%,板间精密度介于-6.1%~6.3%,与Avastin、Actemra、Cetuximab均无交叉,室温稳定性及冻融稳定性良好,无稀释效应.结论:通过方法学的确证,本实验建立的方法可满足抗VEGFR2单克隆抗体在食蟹猴体内的药代动力学研究要求,可用于抗VEGFR2单克隆抗体的检测. Objective:To establish a new and rapid ELISA method for quantitive determination of anti-vascular endothelial growth factor receptor 2 (VEGFR2)monoclonal antibody in the blood serum of Macacafascicularis.Methods:The specific antigen VEGFR2-His bag was coated on the solid phase carrier,and diluted serum was added,followed by goat anti-human IgG-HRP as detecting antibody,TMB color liquid and sulfuric acid as termination liquid.Finally,the absorbance of each well was measured by a microplate reader under 450/560 nm.Results:The linearity range of the new ELISA method was 400~6.25 ng/mL,the lower limit of quantification was 6.25 ng/mL,the within-plate precision ranged from-13.6% to 8.3%,the between-plates precision was-6.1% to 6.3%.There was no cross-reaction with Avastin,Actemra,and Cetuximab.Room temperature and freeze-thaw stability were validated,and no dilution effet was found.Conclusion:This ELISA method met the requirements of pharmacokinetic study,and could be used to determine anti-VEGFR2 monoclonal antibody in cynomolgus monkeys.
出处 《生物技术通讯》 CAS 2016年第3期427-431,共5页 Letters in Biotechnology
关键词 血管内皮生长因子受体2 酶联免疫吸附法 药代动力学 anti-VEGFR2 monoclonal antibody ELISA pharmacokinetics
  • 相关文献

参考文献5

二级参考文献55

  • 1陈志南.基于抗体的中国生物制药产业化前景[J].中国医药生物技术,2007,2(1):2-5. 被引量:11
  • 2汤仲明,刘秀文,柴彪新,屠敏.蛋白质多肽类药物药代动力学研究的方法学和实验设计[J].中国药理学与毒理学杂志,1996,10(3):161-168. 被引量:21
  • 3王连芳 王生玲 等.水中某些无机离子对骨碳除氟的影响[J].地方病通报,1993,18:16-18.
  • 4Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs [ J ].Lancet Oncol, 2001,2 (5) : 278 - 289.
  • 5Folman J. What is the evidence that tumors are angiogenesis-dependent? [J].J Natl Cancer Inst, 1990,82(1) :4 - 6.
  • 6Burke PA, deNardo SJ. Antiangiogenic agents and their proming potential in combined therapy [ J ]. Rev Oncol Hemat, 2001,39( 1 - 2) : 155 - 171.
  • 7Carmeliet P. Angiogenesis in health and disease[J].Nat Med, 2003, 9(6) :653 - 660.
  • 8Sun L, Tran N, Hang C, et al. Design, synthesis, and evaluations of substituted 3-[ (3- or 4-caxboxyexhylpyrrol-2-yl) methylidenyl] indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases[J]. J Med Chem, 1999, 42(25) : 5120 - 5130.
  • 9Carter SK. Clinical strategy for the development of angiogenesis inhibition [ J ]. Oncologist, 2000, 5 ( suppl1) :51 - 54.
  • 10Laird AD, Vajkoezy P, Shawver LK, et al, SU6668 is a potent antlagiogenic and antitumor agent that induces regression of established tumors [ J ]. Cancer Res, 2000, 60(15) :4152 - 4160.

共引文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部